SyB L-1701/L-1702
SyB L-1701: RTD liquid formulation /SyB L-1702: RI administration (generic name: bendamustine hydrochloride hydrate, product name: TREAKISYM
overview
Bendamustine hydrochloride (generic name) is an anticancer drug that has been used for many years in Germany for the treatment of non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia (product name: Ribomustin®). In this field, where there are no superior treatment options, this drug addresses an unmet therapeutic need for patients with relapsed or refractory low-grade non-Hodgkin's lymphoma and mantle cell lymphoma. This alignment with our corporate mission to target such blank therapeutic areas was the decisive factor in our decision to in-license the drug. In Japan, the drug is approved for indolent B-cell non-Hodgkin's lymphoma and mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The Company has also entered into an exclusive license agreement with Eagle Pharmaceuticals for TREAKISYM® liquid injection formulation and rapid infusion administration (RTD formulation and RI administration) in Japan. We are actively engaged in joint research with Kyoto University and others to explore new development possibilities for TREAKISYM®.
What is non-Hodgkin's lymphoma?
Malignant lymphoma is a malignant tumor in which lymphocytes in white blood cells have become cancerous, and is a disease in which swollen lymph nodes and masses form. It is divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma, and the majority of Japanese malignant lymphomas are non-Hodgkin's lymphoma.
Antibody therapy is administered with rituximab as the first-line drug for this disease, but currently there is no established treatment for cases of ineffectiveness or recurrence.
Related Sites
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
Journal of Clinical Oncology (JCO)
NCCN Guldelines
* User registration (free) is required to view information.